CNS pharmaceuticals to grow to $63bn by 2010 forecasts a new report available from Piribo.com

    /24-7PressRelease/ - LONDON, UK, June 15, 2007 - "CNS Market Trends, 2007 to 2010 - Key Market Forecasts and Growth Opportunities" finds that the global CNS market is forecast to expand to US$63.9 billion in 2010 but growth will be limited by mature markets in depression and epilepsy and continued patent expiries for major products.

The report provides an in-depth analysis of the growing market for pharmaceutical treatments for central nervous system (CNS) disorders.

Other key findings from the report include:

- Of the top 20 products by global CNS sales in 2005, 13 generated annual sales in excess of US$1 billion.

- 5 of the top 10 CNS companies AstraZeneca, Forest, GSK, Sanofi-Aventis and Wyeth are forecast to grow their CNS sales over the next five years. J&J, Novartis and Abbott are forecast to suffer declining CNS sales over the next five years.

- A total of 15 pharmaceutical companies were identified as having generated CNS sales in excess of US$1 billion in 2005.

- Topamax was the leading epilepsy drug in 2005 with sales of US$1.7 billion. Other blockbuster epilepsy drugs include the second generation anti-convulsant, Lamictal and traditional anti-convulsant, Depakote.

- The global market for CNS-related pharmaceuticals was dominated by the anti-depressant drug class with a market share of more than 30%

Table of contents:

- Executive Summary
Overview
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

- Chapter 1. Overview of Global CNS Market
Global CNS market
Report overview
Methodology
Sources

- Chapter 2. Key CNS Disease Markets
Key CNS markets
Disease burden
CNS prevalence
CNS mortality
CNS epidemiology
ADHD (Attention Deficit Hyperactivity Disorder)
Alzheimer's disease
Depression
Epilepsy
Migraine
Parkinson's disease
Schizophrenia

- Chapter 3. Key CNS Drug Classes
Key drug classifications
Anti-depressants drug class
Leading anti-depressant drugs
Anti-psychotics drug class
Leading anti-psychotics
Epilepsy drug class
Leading epilepsy drugs
Alzheimer's disease drug class
Leading Alzheimer's disease drugs
Migraine drug class
Leading migraine drugs
ADHD drug class
Leading ADHD drugs
Parkinson's disease drug class
Leading Parkinson's disease drugs
Selected other drug classes
Leading selected other CNS drugs

- Chapter 4. Key CNS Products
Leading products
Top 10 leading CNS drugs
Zyprexa (olanzapine)
Risperdal (risperidone)
Effexor (venlafaxine)
Zoloft (sertraline)
Seroquel (quetiapine)
Lexapro/ Cipralex (escitalopram)
Aricept (donepezil)
Topamax (topiramate)
Lamictal (lamotrigine)
Wellbutrin (bupropion)

- Chapter 5. Key Companies Involved in CNS
Major CNS players
Leading companies
Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Wyeth
Novartis
Forest
Abbott
Sanofi-Aventis


- Chapter 6. Key Trends and Opportunities in CNS
Key disease market forecasts
Global markets
CNS sites
Key drug class forecasts
Anti-depressants
Anti-psychotics
Epilepsy
Alzheimer's disease
Migraine
ADHD
Parkinson's disease
Selected others
Key product forecasts
Zyprexa (olanzapine)
Risperdal (risperidone)
Effexor (venlafaxine)
Zoloft (sertraline)
Seroquel (quetiapine)
Lexapro/ Cipralex (escitalopram)
Aricept (donepezil)
Topamax (topiramate)
Lamictal (lamotrigine)
Wellbutrin (bupropion)
Forecast patent expiries
Company forecasts in the CNS area
Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Wyeth
Novartis
Forest
Abbott
Sanofi-Aventis

"CNS Market Trends, 2007 to 2010 - Key Market Forecasts and Growth Opportunities" is available in pdf format from Piribo. For more information, go to: http://www.piribo.com/search/results.html?k=urc154&x=0&y=0

Piribo product ID: URC154

About Piribo.
Piribo (http:www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

# # #